Synergistic combination of YS-1 and adriamycin inhibits human renal cancer through ERK1/2 signaling pathway in vitro and in vivo

Xiaowen Yu(China Pharmaceutical University), Li Sun(China Pharmaceutical University)
Oncology Reports
January 16, 2017
Cited by 1


Related Papers